Skip to main content

Tagrisso Side Effects

Generic name: osimertinib

Medically reviewed by Drugs.com. Last updated on Aug 25, 2023.

Note: This document contains side effect information about osimertinib. Some dosage forms listed on this page may not apply to the brand name Tagrisso.

Applies to osimertinib: oral tablet.

Serious side effects of Tagrisso

Along with its needed effects, osimertinib (the active ingredient contained in Tagrisso) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking osimertinib:

More common

Less common

Rare

Incidence not known

Other side effects of Tagrisso

Some side effects of osimertinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to osimertinib: oral tablet.

Hematologic

Very common (10% or more): Lymphopenia (63%), thrombocytopenia (54%), anemia (44%), neutropenia (33%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (42%), nausea (17%), decreased appetite (16%), constipation (15%), stomatitis (12%), vomiting (11%)[Ref]

Dermatologic

Very common (10% or more): Rash (e.g., generalized, erythematous, macular, maculopapular, papular, pustular), erythema, folliculitis, acne, dermatitis, acneiform dermatitis (58%), dry skin (e.g., eczema, skin fissures, xerosis) (36%), nail toxicity (e.g., nail and nail bed disorders, nail bed inflammation, nail bed tenderness, nail discoloration, nail dystrophy, nail infection, nail ridging, onychoclasis, onycholysis, onychomadesis, paronychia) (35%), pruritus (17%)

Postmarketing reports: Erythema Multiforme (EMM), Stevens-Johnson Syndrome (SJS), cutaneous vasculitis[Ref]

Metabolic

Very common (10% or more): Hyponatremia (26%), hypermagnesemia (20%)[Ref]

Ocular

Very common (10% or more): Eye disorders (e.g., dry eye, blurred vision, keratitis, cataract, eye irritation, blepharitis, eye pain, increased lacrimation, vitreous floaters) (18%)

Uncommon (0.1% to 1%): Other ocular toxicities[Ref]

Respiratory

Very common (10% or more): Cough (17%), dyspnea (13%)

Common (1% to 10%): ILD/pneumonitis, pneumonia[Ref]

Other

Very common (10% or more): Fatigue (22%)[Ref]

Musculoskeletal

Very common (10% or more): Back pain (13%)[Ref]

Nervous system

Very common (10% or more): Headache (10%)

Common (1% to 10%): CVA/cerebral hemorrhage[Ref]

Cardiovascular

Common (1% to 10%): Cardiomyopathy, venous thromboembolism (includes deep vein thrombosis, jugular venous thrombosis, and pulmonary embolism)

Frequency not reported: QTc interval prolongation[Ref]

Frequently asked questions

References

1. Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.